DOI: https://dx.doi.org/10.18203/2320-6012.ijrms20222056
Published: 2022-08-29

Topical clobetasol propionate 0.025%: a therapeutic dermatologic asset

Deepak Singhal, Revathi Deivasigamani, Bhavik A. Bhavsar, Lakshmi Sitara Ganisetti, Purshotam R. Menghani, Imran Majid, Naveen Kumar Kukkadapu, Gillella Srinivasulu, Sneha Amol, Rani Sudhir Shah, Mashkoor Ahmed Wani

Abstract


Over several decades, topical corticosteroids (TCs) have been used in the treatment of various dermatoses such as psoriasis, contact dermatitis, and eczema, among others. The TCs act by reducing inflammation and irritation after topical application. The therapeutic effect of TCs is bestowed through their diverse biologic properties such as anti-inflammatory, antiproliferative, vasoconstrictive, and antimitotic activity, and its role in the reduction of lymphocyte reactivity, modulation of Langerhans cell expression, cellular and lysosomal membrane stabilization, reduction of recruitment of neutrophils and monocytes, reduction of mast cell density and reactivity, and sensitization of immunoglobulin E. Clobetasol propionate (CP) 0.025% is a class I TC available as a cream formulation. The cream formulation contains half the concentration of conventional CP (0.025%), without the loss of therapeutic potency. The lack of additives such as penetration enhancers (propylene glycol) further prevents cutaneous microbiome alteration. This comprehensive case series covers the potent efficacy and safety of ImpoyzTM (CP) Cream 0.025% in the management of various dermatological disorders.


Keywords


CP 0.025%, Plaque psoriasis, TCs, Psoriasis

Full Text:

PDF

References


Del Rosso JQ. Topical corticosteroid therapy for psoriasis-A review of clobetasol propionate 0.025% cream and the clinical relevance of penetration modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Uva L, Miguel D, Pinheiro C. A Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018.

Sidgiddi S, Naqvi SMH, Shenoy M. Efficacy and safety of novel formulation of clobetasol propionate 0.025% cream in Indian moderate-to-severe psoriasis patients: Phase-2a, randomized 3-arm study. Dermatol Ther. 2021;11(5):1717-32.

Draelos ZD, Fowler JF, Cornelison R. A randomized, parallel group, open label, multicenter study to assess the potential for adrenal suppression and systemic drug absorption following multiple dosing with clobetasol propionate cream (Impoyz™), 0.025% versus clobetasol propionate (Temovate®) cream, 0.05% in subjects with moderate to severe plaque psoriasis. National Society Cutaneous Med. 2018;2(6):410-20.